Boundless Bio Inc. Common Stock

NASDAQ: BOLD
$2.65
-$0.07 (-2.4%)
Real Time Data Delayed 15 Min.

BOLD Stock Chart and Intraday Price

BOLD Stock Data

Asset Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
Sector TECHNOLOGY
Industry GENERAL
Address NONE
Fiscal Year End December
Latest Quarter 2023-12-31
Market Cap 301.12M USD
Shares Outstanding 22,239,300
Audentes Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious and life-threatening rare diseases caused by single gene defects. The company is headquartered in San Francisco, California.

BOLD Articles

Do you have $1,500 you’d like to use to try investing in penny stocks? Some investments in the category can yield outsized gains. But you need to be aware of the risks too.  The truth is that...
A renowned billionaire investor, a French energy giant, and other insiders were scooping up shares of these five stocks as the second quarter began.
Friday's top analyst upgrades and downgrades included Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon Athletica, Sage Therapeutics, Target, Tesla, Trade Desk and Yext.
Audentes Therapeutics shares more than doubled on Tuesday after the firm announced that it would be acquired by Astellas. Although Audentes has only been public for just over three years, this...
Tuesday's top analyst upgrades, downgrades and initiations included Alphabet, Amazon.com, Beyond Meat, CommScope, Enphase Energy, Nabors Industries, Netflix, Nike, Roku, Tesla, Uber Technologies and...
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.